1) Financial Performance Overview
- Q1 2026 revenue increased by 6% to $11.01 billion.
- Adjusted operating income also grew by 6% to $2.4 billion.
- Adjusted EPS rose 6% to $5.44 per share.
- Adjusted operating margin was 21.8%, reflecting strong operational performance despite inflationary pressures.
- Free cash flow for the quarter was $830 million after capital expenditures of $370 million.

2) Segment Performance Insights
- Pharma and Biotech: Achieved mid-single-digit growth, driven by strong performance in bioproduction and clinical research.
- Academic and Government: Revenue declined low single digits due to muted macro conditions, particularly in the U.S. and China.
- Industrial and Applied: Growth was flat, with some strength in chromatography and mass spectrometry.
- Diagnostics and Health Care: Experienced a mid-single-digit decline, although transplant diagnostics showed strong growth.

3) Strategic Developments and Innovations
- Completed the acquisition of Clario, enhancing capabilities in digital endpoint data solutions and contributing $30 million in revenue for Q1.
- Launched several new technologies, including the Thermo Scientific Glacios 3 Cryo-TEM and TSQ Certis Triple Quad Mass Spectrometer, aimed at improving customer productivity and access to advanced capabilities.
- Formed strategic collaborations with NVIDIA and SHL Medical to enhance drug development and delivery systems.

4) Guidance and Market Outlook
- Raised full-year revenue guidance to $47.3 billion to $48.1 billion, reflecting a 6% to 8% growth over 2025.
- Adjusted EPS guidance increased to $24.64 to $25.12, representing 8% to 10% growth over 2025.
- Anticipated organic revenue growth remains at 3% to 4% for the year, with expectations for improved market conditions in the second half.
- Management is actively addressing inflationary pressures and leveraging the PPI Business System for operational efficiency.

5) Challenges and Future Considerations
- The macroeconomic environment remains complex, with potential inflationary pressures due to geopolitical tensions.
- Academic and government segments continue to face headwinds, particularly in the U.S. and China, with expectations for gradual improvement.
- The impact of one less selling day in Q1 and the timing of revenue in Pharma Services affected organic growth metrics.

Bottom line: Thermo Fisher Scientific is positioned for a strong year, with solid financial performance in Q1, strategic acquisitions enhancing capabilities, and an optimistic outlook despite some macroeconomic challenges. The company is well-prepared to navigate these complexities while focusing on innovation and operational efficiency.